Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $4.28 | Change: +$0.16 | %Change: +3.88%
Volume: 21,960 | Day High/Low: 4.30/4.13 | 52 Week High/Low: 10.36/2.40
View modes: 
0 stars

RE:RE:RE:Rock - External Consultant?

I appreciate that this trial outcome has caught virtually everyone off guard to the point of trying to make sense of or rationalizing what could of, should of, been done. Now ann't the time to more
0 stars

RE:RE:Rock - External Consultant?

To be real here, if they had of stopped the trial early due to the lack of an"allergic season" due to the weather conditions, the market would have likely punished the stock price anyways for having more
2.5 stars

RE:Rock - External Consultant?

Following JL's visit to Germany, and provisional conclusions arrived at.......being that patients were selected just before and were fully challenged by intensive grass allergens season in more
5 stars

Rock - External Consultant?

Rock Re the consultant - where did you find that?  Any indication on timing for analysis? Peter  rate and reply
1 star


Kal, it was at 10 bucks a few weeks ago. Of course when it was there this board had 100 dollar sugar plums bouncing around in their heads and Knight taking them out at 40 bucks minimum. No way more
1 star


Those who see a gold and white dress see a price tag of $4.28 per share........ on the other hand ,,,,the pumpers and other futurists see the DRESS as being black and blue,,,,,,,,,,, I hope more
2.5 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

They have submitted the WF10 trial data to an independent expert consultant for comprehensive evaluation of 2014 anomalous results. A 6 month patient recruitment period across multiple allergens in more
5 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

They are due to release the information soon as I recall from this site that it was supposed to be a month. I do hope that they choose their words very carefully as they have written press more
5 stars

RE:RE:RE:RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

You haven't missed anything as of yet Oopsy. I think people are just planing for worst case with WF 10. It will all hinge when the official results come out as to what exactly happened with the more
5 stars

RE:RE:RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

I can't believe any of you being so nonchalant about the notion of throwing in the towel on wf10! Was the success of phase1 a fluke? What happened to the arguments made about possibly more
4 stars

RE:RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

The immune group is WF10....of course both will go. The company has stated many times that WF10 was the future for this company. I still feel that something is going on between the two groups.  rate and reply
4 stars

RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

If WF-10 is scrapped, do you really want the immunology group sticking around? I think WF-10 won't be abandoned, but it is of course a possibility. If the drug is truly the dud the share more
4 stars

RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

Why in God"s name would they even consider dumping the Immune group ? Already investing millions in research and with one successful trial on the books ....the last one we all know Nuvo should more
3 stars

RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

In an earlier post of last week or so, I estimated cash inflows of about $20 million for 2015. it included $0.6 million for P1 royalty. Internal operating margins from manufacturing is quite more
5 stars

This thing has obviously bottomed.

Looks like the bottom is in and all signs are pointing to heading up from here. I see that Seeking Alpha is back promoting it again too with the latest article that was posted here this morning, more
0 stars

RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

Scenario 1 reads: "the company decides to scrap WF-10 and therefore Nuvo as a whole." The word "Nuvo" should be changed to "immunology".  rate and reply
1 star

RE:Nuvo Research Still Worth The Risk - Seeking Alpha

The looming decision on what to do with WF-10 should have a major effect on the direction of Nuvo. The article indicates the company would consider focusing on the topical a side if WF-10 more
0 stars

RE:RE:Did You Know?

No idea if they had received the money by the end of December 2014 but they certaintly would have accounted for it in the results. I don't remember seeing any similar restrictions that MNK more
0 stars

RE:Did You Know?

The first paragraph is certainly news to me. Not that it makes a huge difference to the balance sheet, but do you have any idea whether the milestone payment has actually been made? As for the more
5 stars

Did You Know?

In December 2014, a second generic version of Pennsaid launched in the U.S., which entitled the Company to earn an upfront, non-refundable milestone payment of US$0.5 million ($0.6 million). In more